703 related articles for article (PubMed ID: 12483965)
21. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
22. An 8-12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multi-drug therapy.
Desikan KV; Sundaresh P; Tulasidas I; Rao PV
Lepr Rev; 2008 Sep; 79(3):303-10. PubMed ID: 19009979
[TBL] [Abstract][Full Text] [Related]
23. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
24. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group.
Jamet P; Ji B
Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):195-201. PubMed ID: 7602214
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
[TBL] [Abstract][Full Text] [Related]
28. Bacterial clearance with WHO--recommended multidrug regimen for multibacillary leprosy.
Kishore BN; Shetty JN
Indian J Lepr; 1995; 67(3):301-8. PubMed ID: 8576609
[TBL] [Abstract][Full Text] [Related]
29. Three years assessment of multidrug therapy in multibacillary leprosy cases.
Ganapati R; Revankar CR; Pai RR
Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
[TBL] [Abstract][Full Text] [Related]
30. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
31. Histopathological monitoring of an immunotherapeutic trial with Mycobacterium w.
Mukherjee A; Zaheer SA; Sharma AK; Misra RS; Kar HK; Mukherjee R; Talwar GP
Int J Lepr Other Mycobact Dis; 1992 Mar; 60(1):28-35. PubMed ID: 1602191
[TBL] [Abstract][Full Text] [Related]
32. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
33. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
34. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy.
Kamal R; Natrajan M; Katoch K; Arora M
Indian J Lepr; 2012; 84(4):287-306. PubMed ID: 23720894
[TBL] [Abstract][Full Text] [Related]
35. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
[TBL] [Abstract][Full Text] [Related]
36. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.
Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH
Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211
[TBL] [Abstract][Full Text] [Related]
37. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
38. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
39. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
40. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
Gelber RH; Balagon VF; Cellona RV
Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
